¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ ,lcS J^yr  
JbAmud,  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© Rga *68s|&  
G|YNShK4=9  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© {zalfw{+  
C6'K)P[p  
1.Co-stimulators (or co-stimulating molecules) d7S?"JpV  
"7Z-ACyF5  
2.NK-kB 3EHB~rL/C  
C55Av%-=  
3.Immunoglobulin superfamily IGOEqUw*  
wC?$P  
4.antigen-presenting cell (APC) {y'4&vt<~  
)|/%]@` N  
5.death domain nH<#MG BS  
?,i}Qr [Q  
6.CCR and CXCR ^YJ%^P  
 OA^6l#  
7.Lectin (or mitogen) S_TD o  
M@o^V(j  
8.Clusters of differentiation, CD) }3_ >  
[{`2FR:Cd  
9.B7 family m VFo2^%v  
^GlzKl   
10.Cytotoxic T lymphocyte, CTL) A$i^/hJs  
t3h){jZ  
11.IL-15 and IL-15 receptor (IL-15R) }[R-)M  
{A'*3(8  
12.MHC restriction f> bL }L  
S F`(`h0e  
13.Affinity-chromatography l6 L?jiTl_  
l u8*+.V  
14.Cyctosprin A, CsA 7WwE] ^M  
I _gE`N  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) wSw> UU  
[(gXjt-  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© C}(@cn `L  
rOz1tY)l0d  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 R1D ;  
u88wSe<\X  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£  vP=68muD  
:PtZKt;~X  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ fvcS=nRQv  
dI&Q5M8  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© 5 mC"8N1)  
/isalOT  
ÃâÒßѧרҵ£º +[<YE  
u*TC8! n  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ Pc_aEBq  
"4;nnq  
Ïû»¯ÄÚ¿Æ£º m3TR}=n  
: n QlS  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ 7jgj;%  
Ps74SoD-  
ѪҺ²¡Ñ§×¨Òµ£º xC,x_:R`  
i=cST8!8N  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»